Name: Relias Media
Price range: $

Clinical Briefs By Louis Kuritzky, MD

White-Coat HTN Make Diabetics Walk Treatment of Complicated Grief

Vitamin E, Donepezil and MCI

By Norman R. Relkin, MD, PhD Associate Professor of Clinical Neurology and Neuroscience at New York Presbyterian Hospital-Cornell Campus. Dr. Relkin is on the speaker's bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.

Rifamixin for the Prevention of Traveler’s Diarrhea?

Rifamixin, a nonabsorbed oral antibiotic, is effective for preventing traveler's diarrhea, according to new research.

Pramlintide Acetate Injection (Symlin)

By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Associate Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA. Drs. Chan and Elliott report no financial relationships to this field of study. A synthetic analog of human amylin has been approved for the treatment of type 1 and type 2 diabetics. Pramlintide is a 37-amino acid peptide which differs from human amylin with substitution of three amino acids at positions 25, 28, and 29. It represents the first of a new class of amylinomimetic antidiabetic compounds. It is marketed by Amylin Pharmaceuticals, Inc as Symlin.

Clinical Briefs in Primary Care Supplement

Pharmacology Watch: Antibiotic Treatment of Acute Lower Respiratory Infection

A new study from England defines acute lower respiratory tract infection as an uncomplicated acute illness, with cough as the primary symptom and at least one symptom or sign localized to the lower respiratory tract including sputum, chest pain, dyspnea, or wheeze.

BNP for Differentiating Constrictive Pericarditis vs Restrictive Cardiomyopathy

By Michael H. Crawford, MD Synopsis: BNP levels are significantly elevated in RCM patients as compared to CP patients, and should be a useful noninvasive marker to distinguish the 2 conditions. Source: Leya FS, et al. The Efficacy of Brain Natriuretic Peptide Levels in Differentiating Constrictive Pericarditis From Restrictive Cardiomyopathy. J Am Coll Cardiol. 2005;45:1900-1902.

Aortic Valve Prosthesis-Patient Mismatch (Size Doesn’t Make Much Difference)

By Jonathan Abrams, MD Synopsis: A majority of patients report improvement in functional quality of life early after AVR. Similar functional recovery was demonstrated for patients along the full spectrum of valve sizes indexed to body size, even for values considered to represent severe mismatch for patient size. Factors other than prosthesis-patient size influence functional quality of life early after AVR. Source: Koch CG, et al. Impact of Prosthesis-Patient Size on Functional Recovery After Aortic Valve Replacement. Circulation. 2005:111:3221-3229.

Aortic Stenosis — New Insights

By Jonathan Abrams, MD Professor of Medicine, Division of Cardiology, University of New Mexico, Albuquerque Dr. Abrams serves on the speakers bureau for Merck, Pfizer, and Parke-Davis.

New POTS Treatment?

By Michael H. Crawford, MD Synopsis: Acute acetylcholinesterase inhibition reduced standing heart rate and symptoms in POTS patients. Source: Raj SR, et al. Acetylcholinesterase Inhibition Improves Tachycardia in Postural Tachycardia Syndrome. Circulation. 2005;111:2734-2740.

Clinical

Articles